trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Blocking cholinergic mechanisms in young subjects can artificially induce memory deficits similar to those seen in the aged.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that blocking cholinergic mechanisms in young subjects can artificially induce memory deficits similar to those seen in the aged?

Yes. Blocking cholinergic mechanisms using antagonists like scopolamine is a widely accepted pharmacological method for inducing transient, age-like memory and cognitive deficits in young experimental subjects.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The claim is specific, empirical, and falsifiable. Multiple retrieved papers (such as [0], [7], and [9]) explicitly discuss using scopolamine—a muscarinic cholinergic antagonist—in young animal models to induce memory deficits and mimic aspects of cognitive decline or Alzheimer's disease. There are no papers contradicting this established pharmacological model.

Evidence for · 3
Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (Danio rerio) Model: Involvement of Cholinergic System and Brain Oxidative Stress
2022
Studies use scopolamine, an anticholinergic agent, in young subjects to model cognitive decline and memory loss.
Get citation
Brinza, I., Raey, M. A. E., El-Kashak, W., Eldahshan, O. A., & Hritcu, L. (2022). Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (Danio rerio) Model: Involvement of Cholinergic System and Brain Oxidative Stress. doi.org. https://doi.org/10.3390/molecules27185901

See more details
More for · 2
Exploring the Evolving Role of Scopolamine in Pharmacotherapy: From Cognitive Impairment to Neuroplasticity?-A Narrative Review.
2026
Scopolamine acts as a muscarinic antagonist to induce transient cognitive impairment, serving as a well-established pharmacological model.
Get citation
J, K., P, O., & K, K. (2026). Exploring the Evolving Role of Scopolamine in Pharmacotherapy: From Cognitive Impairment to Neuroplasticity?-A Narrative Review.. doi.org. https://doi.org/10.3390/molecules31071219

Behavioral and Biochemical Evaluation of a Curcumin-Loaded Nano-Liposomal Formulation in a Scopolamine-Induced Mouse Model of Cognitive Impairment.
2026
Scopolamine-induced cognitive impairment models acute cholinergic dysfunction that mimics memory deficits.
Get citation
HY, L., MK, H., GH, J., H, L., YM, K., & HJ, C. (2026). Behavioral and Biochemical Evaluation of a Curcumin-Loaded Nano-Liposomal Formulation in a Scopolamine-Induced Mouse Model of Cognitive Impairment.. doi.org. https://doi.org/10.4062/biomolther.2026.062

What does the evidence say?

The claim is specific, empirical, and falsifiable. Multiple retrieved papers (such as [0], [7], and [9]) explicitly discuss using scopolamine—a muscarinic cholinergic antagonist—in young animal models to induce memory deficits and mimic aspects of cognitive decline or Alzheimer's disease. There are no papers contradicting this established pharmacological model.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work